Pre-myopia
Conditions
Interventions
Group A:0.01% atropine eye drops group was simply given 0.01% atropine eye drops packed with unit dose and without preservatives, once a day, one drop at a time.
Group S:Group S was simply given novel Lenslet-ARray-Integrated spectacle lenses [Hexgon Optimized Reticular Intergration (H.O.R.I), manufacturer: Vision Eye Care Technology, Guangdong, China
registration number: 68736330] worn for 12 hours a day.
Group AS:The combination group was given the combined use of both.
Group E:No clinical intervention was given in the control group.
Sponsors
The Second Hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
6 Years to 12 Years
Inclusion criteria
Inclusion criteria: The inclusion criteria were age 6–12 years, cycloplegic spherical equivalent refraction (SER)> - 0.75 D and = -3.00D.
Exclusion criteria
Exclusion criteria: Exclusion criteria were as follows: Astigmatism or anisometropia >=1.00D in both eyes; children with other combined ocular diseases (eg, amblyopia, strabismus, corneal scar, cataract, glaucoma, or ocular tumor); previous or current treatment with atropine, optical interventions or repeated low-level red-light for myopia control; and allergy to atropine; and inability to comply with the study visit schedule.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of myopia;spherical equivalent refraction (SER); | — |
Secondary
| Measure | Time frame |
|---|---|
| uncorrected visual activity (UCVA);axial length (AL) ;subfoveal choroidal thickness (SFCT) ;Intraocular pressure (IOP) ; | — |
Countries
China
Contacts
Public ContactQi Zhao
The Second Hospital of Dalian Medical University
Outcome results
None listed